Literature DB >> 21986447

Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria.

Rani H Singh1, Meghan E Quirk.   

Abstract

Tetrahydrobiopterin (BH(4)) responsiveness is currently defined as a decrease in plasma phenylalanine concentrations in patients with phenylketonuria (PKU). This definition does not offer insight beyond the initial assessment of patients, which may lead to treatment ambiguity in patients who only experience an initial decrease in plasma phenylalanine concentrations. We present our experience with a novel classification approach using sequentially-applied criteria. Plasma phenylalanine concentrations were measured at baseline and after one month of BH(4) therapy (20 mg/kg/day) in 58 PKU patients (34 M, 24 F; age 17.3±11.0 years). Thirty-two patients (55.2%) were classified as "preliminary responders" at one month, experiencing at least a 15% decrease in plasma phenylalanine concentrations. Preliminary responders' ability to liberalize their dietary restrictions was then systematically assessed. "Definitive responders" were defined as preliminary responders who could increase their dietary phenylalanine tolerance by at least 300 mg/day and lower prescribed medical food needs by at least 25% while maintaining metabolic control (plasma phenylalanine ≤360 μmol/L) and consuming adequate dietary protein. Preliminary responders who could not liberalize their diets according to these criteria were classified as "provisional responders." Nineteen patients (32.8% of patients initiating BH(4) therapy) met the definitive responder criteria, increasing dietary phenylalanine tolerance from 704±518 mg/day to 1922±612 mg/day and reducing medical food to 16.7±19.5% of their baseline prescription. Nine patients (15.5% of patients initiating BH(4) therapy) were classified as provisional responders, all remaining on 100% of their baseline medical food prescription. From this classification approach, a subgroup of provisionally responsive patients emerged who experienced an initial decrease in plasma phenylalanine concentrations but who could not substantially increase their dietary phenylalanine tolerance or decrease medical food needs. Diet liberalization is an essential component of BH(4)-responsiveness classification.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986447      PMCID: PMC4029441          DOI: 10.1016/j.ymgme.2011.09.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  27 in total

1.  The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria).

Authors:  R S PAINE
Journal:  Pediatrics       Date:  1957-08       Impact factor: 7.124

2.  Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy.

Authors:  Nilo Lambruschini; Belén Pérez-Dueñas; Maria Antonia Vilaseca; Anna Mas; Rafael Artuch; Rosa Gassió; Lilian Gómez; Alejandra Gutiérrez; Jaume Campistol
Journal:  Mol Genet Metab       Date:  2005-07-22       Impact factor: 4.797

3.  Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review.

Authors:  V L Brumm; C Azen; R A Moats; A M Stern; C Broomand; M D Nelson; R Koch
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria.

Authors:  Julia B Hennermann; Christoph Bührer; Nenad Blau; Barbara Vetter; Eberhard Mönch
Journal:  Mol Genet Metab       Date:  2005-07-26       Impact factor: 4.797

5.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  S Kure; D C Hou; T Ohura; H Iwamoto; S Suzuki; N Sugiyama; O Sakamoto; K Fujii; Y Matsubara; K Narisawa
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

6.  Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations.

Authors:  Heidi Erlandsen; Angel L Pey; Alejandra Gámez; Belén Pérez; Lourdes R Desviat; Cristina Aguado; Richard Koch; Sankar Surendran; Stephen Tyring; Reuben Matalon; Charles R Scriver; Magdalena Ugarte; Aurora Martínez; Raymond C Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-19       Impact factor: 11.205

7.  Physical growth in phenylketonuria: I. A retrospective study.

Authors:  V A Holm; W E Knox
Journal:  Pediatrics       Date:  1979-05       Impact factor: 7.124

8.  Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations.

Authors:  Angel L Pey; Belén Pérez; Lourdes R Desviat; Maria Angeles Martínez; Cristina Aguado; Heidi Erlandsen; Alejandra Gámez; Raymond C Stevens; Matthías Thórólfsson; Magdalena Ugarte; Aurora Martínez
Journal:  Hum Mutat       Date:  2004-11       Impact factor: 4.878

9.  Nutrient intake and growth of infants with phenylketonuria undergoing therapy.

Authors:  P B Acosta; S Yannicelli; B Marriage; C Mantia; B Gaffield; M Porterfield; M Hunt; N McMaster; L Bernstein; P Parton; M Kuehn; V Lewis
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-09       Impact factor: 2.839

10.  Efficiency of long-term tetrahydrobiopterin monotherapy in phenylketonuria.

Authors:  R Steinfeld; A Kohlschütter; K Ullrich; Z Lukacs
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

View more
  10 in total

1.  Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria.

Authors:  Meghan E Quirk; Steven F Dobrowolski; Benjamin E Nelson; Bradford Coffee; Rani H Singh
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

Review 2.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 3.  Recommendations for the nutrition management of phenylalanine hydroxylase deficiency.

Authors:  Rani H Singh; Fran Rohr; Dianne Frazier; Amy Cunningham; Shideh Mofidi; Beth Ogata; Patricia L Splett; Kathryn Moseley; Kathleen Huntington; Phyllis B Acosta; Jerry Vockley; Sandra C Van Calcar
Journal:  Genet Med       Date:  2014-01-02       Impact factor: 8.822

4.  Long-term follow-up of patients with phenylketonuria treated with tetrahydrobiopterin: a seven years experience.

Authors:  Iris Scala; Daniela Concolino; Roberto Della Casa; Anna Nastasi; Carla Ungaro; Serena Paladino; Brunella Capaldo; Margherita Ruoppolo; Aurora Daniele; Giuseppe Bonapace; Pietro Strisciuglio; Giancarlo Parenti; Generoso Andria
Journal:  Orphanet J Rare Dis       Date:  2015-02-08       Impact factor: 4.123

5.  Genotype-phenotype correlations and BH4 estimated responsiveness in patients with phenylketonuria from Rio de Janeiro, Southeast Brazil.

Authors:  Eduardo Vieira Neto; Francisco Laranjeira; Dulce Quelhas; Isaura Ribeiro; Alexandre Seabra; Nicole Mineiro; Lilian M Carvalho; Lúcia Lacerda; Márcia G Ribeiro
Journal:  Mol Genet Genomic Med       Date:  2019-03-03       Impact factor: 2.183

Review 6.  Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies.

Authors:  Thomas Opladen; Eduardo López-Laso; Elisenda Cortès-Saladelafont; Toni S Pearson; H Serap Sivri; Yilmaz Yildiz; Birgit Assmann; Manju A Kurian; Vincenzo Leuzzi; Simon Heales; Simon Pope; Francesco Porta; Angeles García-Cazorla; Tomáš Honzík; Roser Pons; Luc Regal; Helly Goez; Rafael Artuch; Georg F Hoffmann; Gabriella Horvath; Beat Thöny; Sabine Scholl-Bürgi; Alberto Burlina; Marcel M Verbeek; Mario Mastrangelo; Jennifer Friedman; Tessa Wassenberg; Kathrin Jeltsch; Jan Kulhánek; Oya Kuseyri Hübschmann
Journal:  Orphanet J Rare Dis       Date:  2020-05-26       Impact factor: 4.123

7.  Tetrahydrobiopterin responsiveness in phenylketonuria: prediction with the 48-hour loading test and genotype.

Authors:  Karen Anjema; Margreet van Rijn; Floris C Hofstede; Annet M Bosch; Carla E M Hollak; Estela Rubio-Gozalbo; Maaike C de Vries; Mirian C H Janssen; Carolien C A Boelen; Johannes G M Burgerhof; Nenad Blau; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2013-07-10       Impact factor: 4.123

8.  Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride.

Authors:  Teresa D Douglas; Usha Ramakrishnan; Julie A Kable; Rani H Singh
Journal:  Health Qual Life Outcomes       Date:  2013-12-30       Impact factor: 3.186

9.  One-year follow-up of B vitamin and Iron status in patients with phenylketonuria provided tetrahydrobiopterin (BH4).

Authors:  Kristen D Brantley; Teresa D Douglas; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2018-10-30       Impact factor: 4.123

Review 10.  Protein Substitute Requirements of Patients with Phenylketonuria on BH4 Treatment: A Systematic Review and Meta-Analysis.

Authors:  Fatma Ilgaz; Cyril Marsaux; Alex Pinto; Rani Singh; Carmen Rohde; Erdem Karabulut; Hülya Gökmen-Özel; Mirjam Kuhn; Anita MacDonald
Journal:  Nutrients       Date:  2021-03-23       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.